Credit Suisse maintains AstraZeneca at Neutral, PT $118.00

  • Investing.com
Credit Suisse maintains AstraZeneca at Neutral, PT $118.00

A Credit Suisse analyst maintained AstraZeneca (LON: AZN) at Neutral and a price target of $118.00.

Prior to this rating, AstraZeneca had 22 buy ratings, 6 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on AstraZeneca, click here. For more news on AstraZeneca, click here.

AstraZeneca's stock price closed at $11.0. They are down -99.9% in the last month and up 9.9% in the last 12 months.

According to Investing Pro, AstraZeneca's fair value is $128.4, an upside of 9.3%. AstraZeneca's fair value comes with a low degree of uncertainty, according to InvestingPro.

Check out AstraZeneca's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100